PRKCA and acute myeloid leukemia: The enhanced drug sensitivity resembles AML models, where CD82 targeting improved cytarabine efficacy, but differs mechanistically by exploiting intrinsic apoptosis rather than PKCα/β1-integrin modulation, highlighting tissue-specific pathway engagement.